A macroeconomic approach to evaluating policies to contain antimicrobial resistance: A case study of methicillin-resistant Staphylococcus aureus (MRSA)

Applied Health Economics and Health Policy

Volumn 5, Issue 1, 2006, Pages 55-65

  Smith, Richard D ^a,d   Yago, Milton ^a   Millar, Michael ^b   Coast, Joanna ^c  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH ECONOMICS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; SENSITIVITY ANALYSIS; UNITED KINGDOM;

ANTI-INFECTIVE AGENTS; ECONOMICS; GREAT BRITAIN; HEALTH POLICY; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; STATE MEDICINE;

EID: 33745283935     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200605010-00007     Document Type: Article

References (44)

1. Eandi M, Zara GP. Economic impact of resistance in the community. Int J Clin Pract 1998; 95: 27-38
2. Coast J, Smith RD, Millar MR. An economic perspective on policy antimicrobial resistance. Soc Sci Med 1998; 46: 29-38
3. World Health Organization. WHO global strategy for containment of antimicrobial resistance. WHO: Geneva, 2001
4. Wilton P, Smith RD, Coast J, et al. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy 2002; 7: 111-7
5. Buxton R. Superbugs-the problem of antimicrobial resistance. London: National Institute for Medical Research, 2001
6. Stef L, Bronzwaer M, Cars O, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8: 278-82
7. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial resistant micro organisms in hospitals: a challenge to hospital leadership. JAMA 1996; 275: 234-40
8. Climo MW. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother 1998; 42: 1355-60
9. Davey PG. Growth in the use of antibiotics in the community in England and Scotland in 1980-93. BMJ 1996; 312: 613
10. Coast J, Smith RD, Miller MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ 1996; 5: 217-26
11. Horowitz JB, Moehring HB. How property rights and patents affect antibiotic resistance. Health Econ 2004; 13: 575-84
12. Howard DH. Resistance-induced antibiotic substitution. Health Econ 2004; 13: 585-96
13. Evans RS, Pestotnik SL, Burke JP, et al. Reducing the duration of prophylactic antibiotic use through computer monitoring of surgical patients. DICP 1990; 24: 351-4
14. Rubin N, Foxman B. The cost-effectiveness of placing urinary tract infection treatment over the counter. J Clin Epidemiol 1996; 49: 1315-21
15. Zwar N, Wolk J, Gordon J. Influencing antibiotic prescribing in general practice: a trial of prescriber feedback and management guidelines. Fam Pract 1999; 16: 495-500
16. Sirinavin S, Suvanakoot P, Sathapatayavongs B. Effect of antibiotic order form guiding rational use of expensive drugs on cost containment. Southeast Asian J Trop Med Public Health 1998; 29: 636-42
17. Barlow R. The economic effects of malaria eradication. Amer Econ Rev 1977; 57: 130-48
18. Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002; 415: 680-5
19. Kambou G, Devarajan S, Over M. The economic impact of AIDS in an African country: simulations with a computable general equilibrium model of Cameroon. J Afr Econ 1992; 1: 109-30
20. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999; 43: 459-65
21. Smith RD, Coast J. Controlling antimicrobial resistance: a proposed transferable permit market. Health Policy 1998; 43: 219-32
22. Edwards TH, Hutton JP. Allocation of carbon permits within a country: a general equilibrium analysis of the United Kingdom. Energy Econ 2001; 23: 371-86
23. McKibbin WJ, Wilcoxen PJ. The problem with internationally tradable emission permits for greenhouse gas abatement. Washington, DC: The Brookings Institute, 1997
24. Iorwerth AA, Bagnoli PPB, Dissou Y, et al. A computable general equilibrium analysis of greenhouse-gas reduction paths and scenarios. Ottawa (ON): Economic Studies and Policy Analysis Division, 2000
25. Viguier LL, Mustafa H, Reilly JM. The costs of the Kyoto Protocol in the European Union. Energy Policy 2003; 31: 459-81
26. Hudson EA, Jorgenson DW. US energy policy and economic growth, 1975-2000. Bell J Econ 1974; 5: 461-514
27. Halkos GE. Sulphur abatement policy: implications of cost differentials. Energy Policy 1993 Oct; 21: 1035-43
28. Halkos GE. Economic incentives for optimal sulphur abatement in Europe. Energy Sources 1995; 17: 517-34
29. 2 emission control policies in Japan. Energy J 1993; 14: 83-110
30. Smith RD, Yago M, Millar MR, et al. Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance. J Health Econ 2005; 24: 1055-75
31. Winebrake JJ. The Clean Air Act's sulphur dioxide emissions market: estimating the costs of regulatory and legislative intervention. Resource Energy Econ 1995; 17: 239-60
32. Organization for Economic Development Observer. Trading in pollution. Paris: OECD, 2002
33. Sackett D, Snow JC. The magnitude of compliance and non-compliance. In: Haynes RB, Taylor DW, Sackett D, editors. Compliance in health care. Baltimore (MD): John Hopkins University Press, 1979: 11-22
34. Buckalew LW, Sallis RE. Patient compliance and medication perception. J Clin Psychol 1986; 42: 49-53
35. Shoven JB, Whalley J. Applying general equilibrium. Cambridge (MA): Cambridge University Press, 1992
36. Austin DJ, Anderson RM. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos Trans R Soc Lond B Biol Sci 1999; 354: 721-38
37. Austin DJ, Anderson RM. Transmission dynamics of epidemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in England and Wales. J Infect Dis 1999; 179: 883-91
38. Office of National Statistics. 1995 United Kingdom IO analytical tables. London: ONS, 2002 [online]. Available from URL: http://www.statistics.gov.uk/ themes/economy/articles/nationalaccounts/inputoutput.asp [Accessed 2004 Mar 18]
39. Organization for Economic Development. System of health accounts. Paris: OECD, 2002 [online]. Available from URL: http://www.oecd.org/publications/e- book/8100061e.pdf [Accessed 2004 Mar 18]
40. Public Health Laboratory Service. Surveillance of hospital-acquired bacteraemia in English hospitals, 1997-2002. London: PHLS, 2003
41. Office of Health Economics (2002). OHE compendium 14th edition [online]. Available from URL: http://www.ohe.org/ [Accessed 2003 Oct 13]
42. Piggott JR, Whalley J. UK tax policy and applied general equilibrium analysis. Cambridge: Cambridge University Press, 1985
43. Cox RA. A major outbreak of methicillin resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16). J Hosp Infect 1995; 29: 87-106
44. Baye MR, Maness R, Wiggins SN. Demand systems and the true subindex of the cost of living for pharmaceuticals. Appl Econ 1997; 29: 1179-89